AUA 2018

AUA 2018: Salvage High-Intensity Focused Ultrasound For Locally Recurrent Prostate Cancer after Low-Dose-Rate Brachytherapy: Oncologic and Functional Outcomes

San Francisco, CA (UroToday.com) According to the EAU-ESTRO-SIOG 2018 guidelines, the biochemical disease-free survival for Gleason 6 prostate cancer at 5 years ranges from 71-93% and at 10 years from 65-85%. However, there is a lack of studies evaluating salvage therapies for locally recurrent prostate cancer after low-dose-rate (LDR) brachytherapy. The majority of cases receive androgen deprivation therapy, which is essentially palliative treatment and associated with significant adverse effects such as depression, osteopenia, fatigue, loss of libido, etc.

AUA 2018: Efficacy and Safety of Add-on Mirabegron vs Placebo to Tamsulosin in Men with Overactive Bladder Symptoms MATCH Study

San Francisco, CA (UroToday.com) Benign prostatic hyperplasia (BPH) is a common condition that affects men, and can be associated with secondary overactive bladder (OAB) symptoms. Alpha blockers such as tamsulosin are widely prescribed for the treatment of BPH, but OAB symptoms may continue to persist. Consequently, patients may still complain of voiding symptoms even with an alpha blocker, affecting the quality of life. 

AUA 2018: Insomnia Induces Lower Urinary Tract Symptoms: The Natural History and Risk Factors for LUTS from the Nagahama Longitudinal Study

San Francisco, CA (UroToday.com) The development of lower urinary tract symptoms (LUTS) has been known to be associated with increasing age and bother in both males and females, although the natural history and risk factors for the progression still remain unclear. 

AUA 2018: Extended First Uninterrupted Sleep Period in Elderly Patients Following Treatment with AV002, an Emulsified Low Dose Vasopressin Analog for Nocturia

San Francisco, CA (UroToday.com) Nocturia, characterized by the need to wake at night to urinate, has gained increasing exposure in the urologic community due to its high prevalence and negative impact on quality of life. It often is associated with disrupted sleep, resulting in decreased productivity, poorer overall and mental health, increased risk of falls and fractures, and increased mortality. Studies have also shown it leads to decreased concentration and cognitive function, poorer moods, and reduced energy, as well as increased susceptibility to disease. Unfortunately, treatment options for nocturia remain limited and/or associated with adverse side effects.

AUA 2018: Crowdsourcing Robotics

San Francisco, CA (UroToday.com) Thomas Lendvay, MD from the University of Washington introduced 3 one-minute videos of surgeons performing a step in the robotic prostatectomy and had AUA members (polled 1 week prior), the panelists and attendees of the plenary session (the crowd) rate them based on bimanual dexterity, depth perception, efficiency, sensitivity and robotic control. 

AUA 2018: Complex Cases: Locally Advanced and Metastatic Kidney Cancer

San Francisco, CA (UroToday.com) Christopher Wood, MD from the University of Texas MD Anderson Cancer Center begins the session by presenting complex kidney cancer patients and discussing their management amongst the panelists. The first case is of a 62-year-old patient that presented with decreased appetite, weight loss and a central 6 cm right renal mass found on CT scan by her PCP.

AUA 2018: Phase II Clinical Trial in Prostate Cancer Evaluating (68)Ga-PSMA-11 Detection on both Preoperative PET-CT and Immediate Postoperative Specimen Scanning

San Francisco, CA (UroToday.com) Active surveillance and focal therapy for prostate cancer depend on accurate biopsies for safe and effective treatment. Second, whole gland therapy, such as prostatectomy or radiation therapy, also depend on accurate biopsies for negative margins and precise application of radiation. As such, the question is: What does PSMA PET-CT see and not see in prostate cancer?